636 related articles for article (PubMed ID: 30933235)
61. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
62. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
63. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
64. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.
Hey SP; Gyawali B; D'Andrea E; Kanagaraj M; Franklin JM; Kesselheim AS
J Natl Cancer Inst; 2020 Apr; 112(4):335-342. PubMed ID: 31651981
[TBL] [Abstract][Full Text] [Related]
65. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
66. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
Gyawali B; Rome BN; Kesselheim AS
BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
[TBL] [Abstract][Full Text] [Related]
67. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
Hsiue EH; Moore TJ; Alexander GC
Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
[TBL] [Abstract][Full Text] [Related]
68. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
69. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
70. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
71. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
Nickolich M; Babakoohi S; Fu P; Dowlati A
Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
[TBL] [Abstract][Full Text] [Related]
72. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
73. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
Hilal T; Gonzalez-Velez M; Prasad V
JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
[TBL] [Abstract][Full Text] [Related]
74. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
75. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
76. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
77. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
[TBL] [Abstract][Full Text] [Related]
78. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class.
Samuel JN; Booth CM; Eisenhauer E; Brundage M; Berry SR; Gyawali B
JAMA Oncol; 2022 Jun; 8(6):879-886. PubMed ID: 35482347
[TBL] [Abstract][Full Text] [Related]
79. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
80. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
